文献速递系统性红斑狼疮

丹麦全国队列:抗核抗体阳性多年后系统性红斑狼疮风险升高

Risk of systemic lupus erythematosus elevated years after testing positive for antinuclear antibodies: national cohort study in Denmark.
PubMed 文献 · Rheumatology (Oxford) · 2026-01-01

该研究基于丹麦全国实验室与健康登记数据,随访2000–2017年接受ANA检测且无SLE的个体,评估ANA阳性后SLE的长期风险。结果显示ANA阳性与SLE风险显著升高相关,ANA-CTD阳性风险最高(HR 67.3),且风险在5年后仍持续升高,但绝对风险仍较低。

要点

  • ANA阳性与SLE风险显著升高相关,ANA-CTD阳性HR最高达67.3。
  • 均质型和斑点型SDT-ANA风险最高,5年累积发病率可达9.18%和5.29%。
  • 年轻成人(18–30岁)绝对风险最高,EPT-ANA 5年累积发病率达15.0%。

核心结论

  • ANA阳性与短期及持续长期SLE风险显著升高相关,尤其在年轻成人和高滴度均质型或斑点型个体中。
  • 尽管相对风险高,绝对风险仍较低,需结合临床背景解读ANA结果,并谨慎外推至未选择的初级保健人群。

研究设计与样本

  • 基于丹麦全国实验室与健康登记系统的全国性队列研究,随访2000–2017年接受ANA检测且无SLE的个体。
  • 共纳入342 777名ANA检测个体,其中647例发展为SLE。

主要发现

  • ANA-CTD阳性者SLE风险最高(HR 67.3,95% CI 45.8–99.0),其次为SDT-ANA(HR 18.0,95% CI 14.4–22.5)。
  • 均质型和斑点型SDT-ANA风险最高(HR分别为15.7和7.90),强阳性时5年累积发病率分别达9.18%和5.29%。
  • 风险在首年内最高,但均质型和斑点型在5年后仍持续升高。
  • 年轻个体(18–30岁)绝对风险最高,5年累积发病率ANA-CTD为4.99%、SDT-ANA为4.12%、EPT-ANA为15.0%。

关键数值与推荐

  • ANA-CTD阳性SLE的HR为67.3(95% CI 45.8–99.0)。
  • SDT-ANA阳性SLE的HR为18.0(95% CI 14.4–22.5)。
  • 均质型SDT-ANA的HR为15.7,斑点型为7.90。
  • 强阳性均质型SDT-ANA 5年累积发病率为9.18%,斑点型为5.29%。
  • 18–30岁个体5年累积发病率:ANA-CTD 4.99%、SDT-ANA 4.12%、EPT-ANA 15.0%。

临床怎么用

  • ANA阳性患者应结合临床背景评估SLE风险,尤其关注年轻成人及高滴度均质型或斑点型ANA个体。
  • 尽管相对风险高,绝对风险较低,避免仅凭ANA阳性直接诊断SLE或过度外推至初级保健人群。

局限性

  • 绝对风险较低,结果不宜直接外推至未选择的初级保健人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The objective of this study was to assess the long-term risk of SLE following ANA positivity in a nationwide cohort. METHODS: We followed ANA-tested, SLE-free individuals from 2000-2017 using national laboratory and health registers. ANA tests included ELISA-like CTD screening (ANA-CTD), single-dilution ANA (SDT-ANA) at dilution 1:160, and end-point ANA titre (EPT-ANA) at dilutions of 1:160-1:1280. In routine practice, ANA-CTD is often used in general practice, and SDT-ANA and EPT-ANA in secondary and tertiary care. Hazard ratios (HR) of SLE were estimated using Cox models, and 5-year cumulative incidence using Kaplan-Meier methods. RESULTS: Among 342 777 ANA-tested individuals, 647 developed SLE. ANA positivity was strongly associated with SLE. ANA-CTD positivity conferred the highest risk (HR 67.3, 95% CI 45.8-99.0), followed by SDT-ANA (HR 18.0, 95% CI 14.4-22.5). Homogeneous and speckled SDT-ANA patterns carried the greatest risk (HR 15.7 and 7.90), with 5-year cumulative incidences up to 9.18% and 5.29% for strongly positive ANA intensity. Risk was highest within the first year, but remained elevated beyond 5 years for homogeneous and speckled patterns. Absolute risks were highest in younger individuals (18-30 years), reaching 5-year cumulative incidences of 4.99% for ANA-CTD, 4.12% for SDT-ANA, and 15.0% for EPT-ANA. CONCLUSION: ANA positivity was associated with markedly elevated short-term and sustained long-term SLE risk, particularly in younger adults and individuals with high-intensity homogeneous or speckled patterns. Nonetheless, absolute risk remained low, highlighting the need to interpret ANA results within a broader clinical context, and caution against direct extrapolation to unselected primary care populations.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. de Saint-Aubain CJ, Westermann R, Lauridsen KB, et al. Risk of systemic lupus erythematosus elevated years after testing positive for antinuclear antibodies: national cohort study in Denmark. Rheumatology (Oxford). 2026. PMID: 42036827. doi:10.1093/rheumatology/keag227

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。